Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 04/30
| 07-2023 | 04-2023 | 01-2023 | 10-2022 | 07-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,695 | 5,141 | 7,376 | 9,183 | 11,527 |
| TOTAL | $2,414 | $5,836 | $8,417 | $10,334 | $12,115 |
| Non-Current Assets | |||||
| PPE Net | 214 | 80 | 85 | 91 | 96 |
| TOTAL | $214 | $80 | $85 | $91 | $96 |
| Total Assets | $2,628 | $5,916 | $8,502 | $10,425 | $12,211 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,741 | 2,870 | 2,643 | 1,637 | 1,029 |
| TOTAL | $2,741 | $2,870 | $2,643 | $1,638 | $1,029 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $2,741 | $2,870 | $2,643 | $1,638 | $1,029 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 72 | 72 | 71 | 71 | 71 |
| Common Shares | 10 | 0 | 10 | 10 | 10 |
| Retained earnings | -47,600 | -44,073 | -40,767 | -35,342 | -32,232 |
| Other shareholders' equity | -14,883 | -14,883 | -14,883 | -14,883 | -14,883 |
| TOTAL | $-113 | $3,046 | $5,860 | $8,787 | $11,182 |
| Total Liabilities And Equity | $2,628 | $5,916 | $8,502 | $10,425 | $12,211 |